Taylor Robichaux/LinkedIn
Jan 9, 2026, 07:07
Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
Taylor Robichaux, Emergency Medicine Clinical Pharmacist at Ochsner LSU Health, shared on LinkedIn:
”The landscape for cTTP is evolving!
Check out our paper on recombinant ADAMTS13 in JADPRO!
It was a privilege to work with such a great group of pharmacists.
Congratulations to all the authors!”
Read the full article here.
Article: Recombinant ADAMTS13: An Enzyme Replacement Therapy for the Management of Congenital Thrombotic Thrombocytopenic Purpura
Authors: Taylor Robichaux, Kathryn Dane, Christopher Parish, Justin Arnall, Donald Moore
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 12, 2026, 14:18Jean Jacques Kiladjian: Grateful to the MSH for the invitation to ‘Highlights of ASH’ in Asia-Pacific 2026
-
Apr 12, 2026, 14:15Paritosh Garg: A fibrotic marrow is not always PMF
-
Apr 12, 2026, 14:13Scott Woller: ACC/AHA Guidelines and the Role of Pulmonary Embolism Response Teams
-
Apr 12, 2026, 13:55Ifeanyichukwu Ifechidere: When Fibrinogen isn’t Really Fibrinogen
-
Apr 12, 2026, 13:53Alan Nurden: A Contemporary Update on the Pathogenesis of Inherited Platelet Dysfunction
-
Apr 12, 2026, 13:47Kalyan Roy: Visual Inspection of Blood Bags and Blood Products
-
Apr 12, 2026, 13:44Francisco Ujueta: PAD VS CAD – Why Individualized Antithrombotic Strategies Matter
-
Apr 12, 2026, 13:42William Aird: Anemia of Inflammation Not Just a Trade-Off but a Possible Compensation
-
Apr 12, 2026, 13:38Emmanuel J Favaloro: D-dimer testing in VTE diagnostic management studies